Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial

BACKGROUND: Montelukast, a safe drug widely use in asthmatic patients, may be an adjuvant in the treatment of Covid-19, either by improving lung injury and inflammation, or by acting as an anti-viral drug. We aim to assess the efficacy and safety of montelukast as add-on treatment in patients with C...

Descripción completa

Detalles Bibliográficos
Autores principales: Tavares, Margarida, Farraia, Mariana, Silva, Susana, Ribeiro, Ana Margarida, Severo, Milton, Paciência, Inês, Ribeiro, Raquel, Hespanhol, Venceslau, Guimarães, João Tiago, Almeida, Jorge, Magro, Fernando, Sarmento, António, Oliveira, Ana Marta, Moreira, André
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049153/
https://www.ncbi.nlm.nih.gov/pubmed/33869886
http://dx.doi.org/10.1097/j.pbj.0000000000000134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049153/
https://www.ncbi.nlm.nih.gov/pubmed/33869886
http://dx.doi.org/10.1097/j.pbj.0000000000000134

Ejemplares similares